1st U.S. Biosimilar Arrives: Zarxio Launches; Legal Saga Ongoing

The day after Amgen was dealt another blow at the U.S. Court of Appeals for the Federal Circuit in the company's failed attempt to keep Novartis unit Sandoz from launching its biosimilar Zarxio (filgrastim-sndz), the latter firm moved forward with putting the medicine on the U.S. market – the first biologic copycat available to Americans.